Mr. Hugh MacNaught reports

LISHMAN GLOBAL PLACES FIRST ORDER FOR VENTRIPOINT'S VMS+ TECHNOLOGY

Ventripoint Diagnostics Ltd. has received the first purchase order from Lishman Global Inc. for VMS+ technology to be used within its echocardiography image platform in the People's Republic of China. Lishman will use the technology within six hybrid echocardiography systems built to support technology demonstration, clinical validation, and regulatory submission to the China Food and Drug Administration (CFDA).

Previously, Lishman's Chinese subsidiary had received CFDA approval and a certificate of production (CoP) from the CFDA in the People's Republic of China for the VMS+ product used for analysis of the right ventricle (RV) only of the heart. Through the manufacture and sale of a limited number of these systems, Lishman was able to develop market insights, validate the market opportunity, identify and engage with channel partners, and build market awareness.

With 32,000 hospitals and rapidly aging demographics, China presents one of the largest single-country opportunities for cardiovascular diagnostics. Cardiovascular disease is the leading cause of hospital admissions, accounting for approximately 23 per cent of admissions -- nearly double the rate in North America -- driven by an aging population and high prevalence of hypertension. Echocardiography usage is especially high in China and is often mandated prior to surgical procedures, increasing the demand for high-quality, affordable and accessible diagnostic imaging.

"We look forward to working with our Chinese partners to include the newer capabilities of VMS+ into their hybrid echo product," stated Hugh MacNaught, president and chief executive officer. "Expanding functionality to all four cardiac chambers will provide greater accuracy of echo studies for a wider range of cardiopulmonary indications. Ventripoint's proprietary AI enhancement to echocardiography is an important tool for healthcare systems globally. It enables the enhancement of the vast installed base of echocardiography systems to deliver accurate, affordable and accessible cardiac imaging."

"We are excited to work with Ventripoint to begin the work of integrating VMS+ within our new products, securing CFDA approval and building awareness of our new solutions to the Chinese clinical community," stated Paul Gibson, chief technology officer of Lishman.

About Lishman Global

Lishman Global was establish in 2012 to assist companies to safely enter the Chinese market. The company's partnership model allows foreign companies to navigate the complex network of regulatory approvals and multilevel distribution channels common in the Chinese medical device market.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.